The mechanisms contributing to the persistent activation of macrophages in rheumatoid arthritis (RA) are not fully understood. Some studies suggest that endogenous toll-like receptor (TLR) ligands promote the chronic infl ammation observed in RA. The objective of this study was to identify endogenous TLR ligands expressed in RA synovial tissue (ST) based on their ability to bind the extracellular domains of TLR2 or TLR4. Methods A yeast two-hybrid cDNA library was constructed from ST obtained by arthroscopy from patients with RA and screened using the extracellular domains of TLR2 and TLR4 as the bait. Interactions between TLRs and Snapin were demonstrated by reciprocal co-immunoprecipitation. ST was examined by histology, and single-and two-colour immunohistochemistry and quantitative reverse transcriptase PCR. Snapin (SNAP -associated protein) expression in macrophages was examined by Western Blot analysis and confocal microscopy. The ability of Snapin to activate through TLR2 was examined. Results Employing a yeast two-hybrid system, Snapin was the most frequently identifi ed molecule that interacted with TLR2. These results were confi rmed by pull-down of in vitro-expressed Snapin together with TLR2.
INTRODUCTION
Macrophages are critical to the destruction of cartilage and bone observed in rheumatoid arthritis (RA). [1] [2] [3] RA synovial tissue (ST) macrophages express high levels of tumour necrosis factor α (TNFα), interleukin 1β (IL-1β), granulocyte-macrophage colony stimulating factor , IL-6, IL-8, collagenase (MMP1) and stromelysin (MMP3), all mediators of infl ammation and joint destruction. 4 Supporting a central role for macrophages, inhibition of TNFα or IL-1β suppresses synovitis and joint destruction in RA. Further, the number of macrophages in the sublining of RA ST correlates with clinical response. 5 6 Although the mechanisms EXTENDED REPORT
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Bo Shi, 1 QiQuan Huang, 1 Paul Peter Tak, 2 Margriet J Vervoordeldonk, 2 Chiang-Ching Huang, 3 Andrea Dorfl eutner, 1 Christian Stehlik, 1 Richard M Pope 1 contributing to the persistent activation of macrophages are not clear, in addition to immune complexes, other potential mechanisms have been described, including the activation of toll-like receptors (TLRs). 4 7 TLRs are pattern-recognition receptors, best characterised for their role in activation of monocytes, macrophages and dendritic cells. 8 TLR2 and TLR4 were both expressed in the RA joint macrophages when ST was examined by immunohistochemistry. [9] [10] [11] We recently documented the increased expression of TLR2 and TLR4 on RA synovial fl uid (SF) macrophages and the increased response of these macrophages to microbial TLR2 and TLR4 ligands. 12 In RA, infl ammation results in joint damage and the expression and release of a variety of molecules that may be capable of acting as endogenous TLR2 and TLR4 ligands, including heat shock protein (HSP) 60 and 70, 13 14 extra domain A fi bronectin, 15 and High Mobility Group Box chromosomal protein 1 (HMGB1) 16 . Recent data suggests a role for the 96-kDa glycoprotein 96 (gp96), an endoplasmic reticulum stress response protein, 17 and the extracellular matrix glycoprotein tenascin C 18 as potential endogenous TLR2 and TLR4 ligands in RA. However, none of these previously identifi ed endogenous TLR ligands were discovered based on their local expression in RA ST and the ability to bind TLR2 or TLR4.
To identify endogenous TLR ligands in RA, we generated and screened a yeast two-hybrid library constructed with RA ST using the extracellular domains of TLR2 and TLR4. We identifi ed Snapin (SNAP -associated protein), which is important in synchronisation of synaptic vesicle fusion and late endosomal transport in neurons. 19 20 Snapin bound to and activated TLR2 and was highly expressed in RA ST macrophages and was present in RA SF. These observations identify Snapin as a novel endogenous TLR2 ligand that may contribute to the pathogenesis of RA.
MATERIALS AND METHODS Patients
To synthesise a cDNA library, RA ST from 8 patients with active disease (online supplementary table 1) were obtained at the time of arthroscopy. 21 Patients with RA were diagnosed according to the American College of Rheumatology classifi cation criteria. 22 Additional ST was obtained at the time of joint arthroplasty on patients with RA (n=7), osteoarthritis (OA, n=8), and from individuals with no apparent arthritis (arthritis-free controls, n=7), at the time of surgery or autopsy, were from Northwestern Memorial Hospital or the National Disease Research Interchange. SFs were obtained from patients with infl ammatory arthritis (online supplementary table 2) at the time of therapeutic arthrocentesis.
Yeast two-hybrid assay
Yeast two-hybrid screening was performed using the matchmaker yeast two-hybrid system3 (Clontech, Mountain View, CA, USA). The bait constructs were generated by inserting cDNAs encoding the extracellular domains of human TLR2 (amino acids 18-587), TLR4 (amino acids 25-632), COOHterminal truncated TLR2 (amino acids 18-433) or TLR4 (amino acids 25 to 419) in frame with the GAL4 DNA binding domain of pGBK-T7, and were transformed into AH109 yeast. For the RA cDNA library, cDNAs were amplifi ed from pooled mRNAs isolated from 8 RA STs, cloned into pGADT7-RecAB, and transformed into Y187 yeast. Mating was performed between AH109 and Y187. Positive yeast colonies were selected twice by X-α-galactosidase activity and leucine, tryptophan, histidine and adenine auxotrophy. Plasmid DNA was sequenced and TLRinteracting genes identifi ed by BLAST (Basic Local Alignment Search Tool) analysis. 23 Co-purifi cation assay TLR2-Fc, TLR4-Fc and the Fc control fusion proteins were generated by cloning of the extracellular domains of human TLR2, TLR4 or the signal peptide of TLR2, as the Fc control, into pFUSE-hIgG1-Fc1 (InvivoGen, San Diego, CA, USA) in frame with human IgG1-Fc 17 . His-tagged Snapin was cloned into pcDNA3-His (Invitrogen, Grand Island, NY, USA). All proteins were stably expressed in CHO cells. 17 
Immnuohistochemistry, immunoblot analysis, macrophage isolation, immunofl uorescence microscopy and detection of Snapin in SF
The details of these procedures are presented in the online supplementary materials.
TLR2 Activation
The human embryonic kidney 293 (HEK-293) cell line stably expressing human TLR2, and a nuclear factor κB (NF-κB) regulated reporter gene (HEK-TLR2)(InvivoGen) was employed to identify TLR2-activating ligands. HEK-TLR2 cells (1×10 5 /well) were seeded into 96 well plates and incubated with recombinant Snapin (0-10 μg/ml) (Prospec, Renouot, Israel) for 16 h at 37 o C. Where indicated, cells were preincubated with neutralising anti-TLR2 antibody (5-10 μg/ml) for 10 min before adding Snapin, or Snapin was denatured by heat or proteinase K digestion as previously described. 17 Activation of macrophages by RA SF RA SFs were diluted 1:4 then preincubated with monoclonal anti-Snapin antibody or immunoglobulin G (IgG) isotope control (10 μg/ml) for 1 h. The fl uids were added to in vitrodifferentiated macrophages for 4 h. The cells were isolated, the RNA extracted employing Trizol and quantitative reverse transcriptase PCR (qRT-PCR) was performed to detect TNFα mRNA expression.
Statistical analysis
Experimental data are presented as the mean±SE. Comparisons between three or more groups were performed by one-way analysis of variance, followed by the Tukey test. Comparisons between two groups unevenly distributed were performed by the Mann-Whitney U test. The statistical differences between group.bmj.com on May 2, 2012 -Published by ard.bmj.com Downloaded from matched pairs were determined by the paired t test. Pearson's product-moment correlation was used to defi ne the relationship between variables.
RESULTS

Yeast two-hybrid screen
To identify novel endogenous TLR2 and TLR4 ligands, RNA was isolated from the tissues of eight patients with active RA, transcribed into cDNA and cloned in frame with the GAL4 activation domain. This library was expressed in yeast and mated to yeast expressing the extracellular domains of TLR2 or TLR4 linked to the GAL4 binding domain. With the yeast two-hybrid system, a total of 60 coding sequences representing 11 unique proteins were identifi ed by their interaction with TLR2, while 55 sequences, representing 34 unique proteins interacted with TLR4, including COPS5 and ATP1B3, which were frequently identifi ed. The most frequently identifi ed TLR-interacting molecule was Snapin, a SNARE (soluble-N-ethylmaleimide -sensitive factor accessory protein (SNAP) receptor) complex protein originally described in neurons. 19 20 24 Of all coding sequences encoding potential TLR2 interacting proteins, Snapin was identifi ed 33 times, thus representing 55% of all TLR2-binding clones, but it represented only 13% of those interacting with TLR4.
Snapin binds to TLR2
In order to confi rm that Snapin specifi cally interacts with TLR2, either full-length Snapin or Snapin (60-136), lacking the NH 2 terminal region were in vitro expressed and subjected to a binding assay. Recombinant TLR2-Fc, TLR4-Fc and Fc were immobilised on protein-G agarose and incubated with full-length Snapin or Snapin (60-136). Both full-length Snapin and Snapin (60-136) co-purifi ed with TLR2-Fc, but not TLR4-Fc or Fc control Therefore, Snapin specifi cally binds to TLR2, and this interaction requires the C-terminus (aa 60-136) of Snapin.
Snapin is expressed in RA ST
Studies were performed to determine if Snapin could be detected in RA ST by immunohistochemistry. Snapin was readily detected in RA ST (fi gure 2E,F), compared with arthritis-free control and OA STs (fi gure 2A-D). There was no difference in the lining thickness between the groups; however, the infl ammation score (p<0.05-0.01) was increased in the RA compared with the control and OA STs, while blood vessels were increased in RA compared with the arthritis-free controls (p<0.05) (fi gure 2G). The percentage of Snapin-positive cells and the Snapin expression score, refl ecting the percent positive and intensity of staining, were both signifi cantly (p<0.05-0.01) increased in the sublining of the RA STs compared with the OA or arthritis-free controls (fi gure 2H,I). In the lining, the Snapin staining was not signifi cantly different between any of the clinical groups. Although there was no signifi cant correlation when the RA STs were examined alone, when all the tissues were examined together, Snapin in the sublining, as per cent positive or expression score, correlated with infl ammation (r=0.72-0.79, p<0.01-0.001) (sublining Snapin percent vs infl ammation, online supplementary fi gure 1A), while Snapin in the sublining correlated with blood vessels (r=0.57-0.61, p<0.01) (online supplementary fi gure 1B). Therefore, Snapin is signifi cantly increased in RA compared with arthritis-free and OA STs, and its expression correlated with infl ammation and angiogenesis, and its expression is not disease specifi c. Two-colour immunohistochemistry demonstrated that the majority of CD68+ macrophages, especially those in the sublining region, expressed Snapin (fi gure 3A). Additionally, within lymphoid aggregates, some CD3+ T cells also expressed Snapin (data not shown). By Western Blot analysis, Snapin was weakly expressed in normal and RA monocytes, but highly and comparably expressed in in vitro-differentiated macrophages (fi gure 3B,C). By immunofl uorescence microscopy, Snapin was expressed in macrophages in a diffuse granular pattern (fi gure 3D). Snapin did not co-localise with actin or podosomes (data not shown), but co-localised with Rab7, a marker for late endosomes (fi gure 3D).
To determine the relationship of ST Snapin to clinical activity, Snapin was quantifi ed by qRT-PCR in the STs of 13 patients (online supplementary table 1) with RA. Snapin was significantly (p=0.025) higher in those who had been treated with a single DMARD, compared with those treated with two or more (fi gure 4A). Further, Snapin was signifi cantly correlated with the number of swollen joints (r=0.60, p=0.03) (fi gure 4B). The correlation with 28-joint disease activity score (DAS28) (r=0.34) did not reach signifi cance, likely because the DAS28 scores were 
Snapin is detected in RA SFs
Since TLR2 is expressed on the cell surface, SFs were examined for the presence of extracellular Snapin. By Western Blot, Snapin was detected in the majority of RA SFs examined; however, the level of expression was variable (online supplementary fi gure 2). Although it was not detected in the four OA or fi ve psoriatic arthritis SFs (data not shown), Snapin was present in the SF of a patient with reactive arthritis (online supplementary fi gure 2), demonstrating that Snapin in SF is not specifi c for RA.
Snapin activates TLR2
Since Snapin interacted with TLR2, studies were performed to determine if Snapin was capable of activating TLR2. Recombinant Snapin-activated NF-κB activity in HEK-TLR2 cells in a dose-dependent manner (fi gure 5A). Since Snapin was expressed and purifi ed from bacteria, control experiments were performed to determine if this activity was specifi cally attributed to Snapin. Heat denaturation or proteinase K digestion of recombinant Snapin-abolished TLR2 activation by Snapin (fi gure 5B), suggesting that TLR2 stimulation was due to Snapin and not a potential microbial contaminant. Further, addition of TLR2 neutralising antibodies, but not control IgG, signifi cantly and dose-dependently suppressed the ability of Snapin to activate HEK-TLR2 cells, demonstrating that the activation was mediated through TLR2.
Experiments were performed to determine if Snapin present in RA SFs was capable of activating macrophages. From another study, four RA SFs were identifi ed based on their ability to activate in vitro-differentiated macrophages determined by the induction of TNFα mRNA. This activation was suppressed by 77+9% (SE) by preincubating the macrophages with neutralising anti-TLR2 antibodies (data not shown). To determine if Snapin might contribute to the observed macrophage activation, the SFs were preincubated with a monoclonal anti-Snapin antibody. The activation of macrophages by three of the four SFs was suppressed by the anti-Snapin antibody a mean of 47±2% (p=0.03) compared with isotype controls (fi gure 6). When all four fl uids were included, the reduction was 44±3% (p=0.09). The SF that did not suppress was from a patient who had recently developed a lymphocytic lymphoma and that fl uid only resulted in a 4.3-fold activation of macrophages, which may have limited the ability to observe meaningful change. 
DISCUSSION
Employing a yeast two-hybrid system, Snapin was the most frequently identifi ed RA ST-expressed protein interacting with TLR2. Snapin was originally described in neurons isolated by its ability to bind to SNAP-25, a member of the SNARE family. 24 The SNARE family consists of at least 38 members that are critical for the transport of vesicles within cells, promoting the docking of lipid bilayers. 25 Snapin-defi cient neurons demonstrate defects in synaptic vesicle fusion which impairs the synchronisation of neurotransmitter release. 20 Further, Snapin is critical for neuronal homeostasis through its role in promoting traffi cking of late endosomes to lysosomes mediated through interaction with dynein, resulting in reduced lysosomal-degradative capacity. 19 The role of Snapin in macrophages is unclear, although Snapin does co-localise with Rab7 in macrophages, thus indicating its presence within the late endosomes. 26 The results demonstrate that although Snapin is highly expressed in RA, it is not specifi c for the disease. Some OA STs also expressed Snapin, and Snapin was detected in the SF of a patient with reactive arthritis. Snapin was readily detected in control and RA in vitro-differentiated and RA ST macrophages and was present in RA ST T cells, consistent with an earlier study identifying Snapin in T cells. 27 Further, Snapin has been detected in a variety of tissues in addition to brain. 28 Even though Snapin expression correlated with infl ammation histologically and clinically, incubation of normal macrophages with TNFα or microbial TLR2 or TLR4 ligands failed to further induce the expression of Snapin (not shown). The mechanism by which infl ammation induces Snapin expression remains to be determined.
The approach used in this study was novel, based on screening employing the extracellular domains of TLR2 and TLR4 to identify interacting proteins expressed by an RA ST cDNA library. Earlier studies using a candidate molecule approach, identifi ed proteins highly expressed in the RA joints as those that were capable of activating TLR2, and TLR4, including HSP60, HSP70 13 14 and HMGB1. 16 However, these studies did not document the ability of the potential endogenous ligands to bind to TLR2, or TLR4, and other investigators were not able to reproduce TLR activation employing very low endotoxin HSP60 and 70. 29 30 Recombinant serum amyloid A (SAA) was shown to directly interact with and activate through TLR2. 31 While SAA is highly expressed in the circulation of patients with RA, in contrast to recombinant SAA, SAA isolated from the circulation of patients with RA did not activate peripheral blood mononuclear cells. 32 We previously demonstrated that gp96, which is highly expressed in RA ST, was also capable of binding to and activating TLR2. 17 In summary, although a number of potential endogenous TLR2 ligands have been described in RA, not all have been shown to bind and activate TLR2.
In the current study, Snapin was capable of binding TLR2, and recombinant Snapin also specifi cally promoted TLR2-mediated NF-κB activation. These observations, and the fact that Snapin was identifi ed extracellularly in SF, support a role of Snapin as an endogenous TLR2 ligand that is capable of contributing to the pathogenesis of RA. Since it is possible that microbial contamination might contribute to HEK-TLR2 activation, in addition to employing commercially available recombinant Snapin (fi gure 5), we expressed and purifi ed (His) 6 -tagged recombinant Snapin, which was isolated and extensively washed employing nickel affi nity sepharose. While the level of endotoxin measured in this preparation of Snapin was below that capable of activating HEK-TLR4 cells, it activated HEK-TLR2 cells (not shown). Previous studies demonstrated that heat denaturation and treatment with proteinase K did not signifi cantly reduce the ability of known microbial TLR2 ligands Staphylococcus aureus lipoteichoic acids and Escherichia coli 0111:B4 peptidoglycans to activate through TLR2. 31 In the current study, heat denaturation and proteinase K digestion prevented Snapin-mediated TLR2 activation. These observations suggest that the activation of HEK-TLR2 cells was not due to a contaminating microbial ligand.
Employing the yeast two-hybrid screen, we did not detect any of the earlier identifi ed potential TLR2 and TLR4 ligands that have been implicated in RA, including gp96. 17 This may be related to the fact that the molecular weight of the cDNA synthesised from RA ST ranged from 0.8 to 2.3 kb, averaging 1.5 kb. Therefore, the library represented primarily smaller proteins, such as Snapin, or the COOH-terminal regions (including 3′ untranslated regions) of the larger proteins. It is possible that these regions did not contain the domains responsible for binding TLR2 or TLR4. It is also possible that the previously identifi ed ligands may not interact with TLR2 or TLR4 in the yeast two-hybrid assay, or that they may not have been expressed by our cDNA library.
A number of observations support the role of TLR2 signalling in the pathogenesis of RA. Culture supernatants from RA STs activated macrophages, and this response was inhibited by suppression of MyD88 or Mal/TIRAP, which mediate both the TLR2 and the TLR4 downstream signalling. 33 In addition, our unpublished observations demonstrate that RA SFs are capable of activating macrophages mediated through TLR2 (not shown). Employing some of these fl uids, our data suggest that Snapin in RA SFs contributed to macrophage activation, although additional TLR ligands and cytokines may also have contributed. In addition, we cannot exclude that Snapin in the SFs may have activated macrophages through a mechanism other than TLR2. Further supporting an important role for TLR2 signalling in RA, a recent study demonstrated that a neutralising monoclonal antibody to TLR2 suppressed the spontaneous release of cytokines from RA ST cultures. 34 Collectively, these observations suggest that endogenous TLR2 ligands are present in infl amed RA ST, and that they are capable of contributing to the perpetuation of chronic infl ammation, thus supporting a potential role for neutralising TLR2 signalling as a novel approach to therapy in RA. 
